Evidence map›Paper›PMID 37789318›Full record

ArticleBMC biotechnology2023

Engineered FGF19

Lu Shi, Tiantian Zhao, Lei Huang, Xiaomin Pan, Tianzhen Wu, Xin Feng, Taoli Chen, Jiamin Wu, Jianlou Niu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. The Role of Gut Microbiota in Liver Regeneration After Partial Hepatectomy: New Evidence From Animal and Human Studies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lu Shi *School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Tiantian Zhao *School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Lei HuangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Xiaomin PanSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Tianzhen WuSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Xin FengSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Taoli ChenSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Jiamin WuSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. Jiaminwu@wmu.edu.cn.
Jianlou NiuPingyang Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325499, Zhejiang, China. niujianlou@wmu.edu.cn.
Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe major safety concern of the clinical application of wild type FGF19 (FGF19

resultsWe found that, similar to that of FGF19

conclusionsTogether, our findings raise hope that FGF19

Indexed as

CholestasisCholestasis, IntrahepaticAnimalsBile Acids and SaltsDisease Models, AnimalFibroblast Growth FactorsLiverMiceBile Acids and Saltsfibroblast growth factor 15, mouseFibroblast Growth FactorsBile acidsFGF19Hepatocellular carcinomaInflammationIntrahepatic cholestasis

Identifiers

PMID37789318
PMCPMC10548598
OpenAlexW4387305992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.